Normal view MARC view ISBD view

Borderline resectable pancreatic tumors: multimodal approach improves outcomes

In HPB
By: Mitra A.
Contributor(s): Shrikhande SV | Goel M | Engineer R | Ostwal V | Patkar S | Shetty N | .
Material type: materialTypeLabelArticleSeries: Vol 17 Issues Suppl 2.Publisher: 2015Subject(s): Multimodal approach | Pancreatic tumors | DDC classification: In: HPBSummary: Objectives: Borderline Resectable Pancreatic Tumors pose a management challenge. We aimed to assess the impact of multimodality approach on outcomes of borderline resectable (BR) pancreatic tumors. Methods: Prospective database (January 2007July 2014) was analyzed retrospectively. Pancreatic tumors were segregated into BR and locally advanced unresectable (LA) groups. The decision to operate upfront or offer neoadjuvant therapy was based on predefined radiologic criteria and on joint clinic decisions. Results: There were 104 pancreatic tumors. 84 were BR and 20 LA. In the BR group, 39 were treated with neoadjuvant therapy and 38 underwent upfront resection. 7 were lost to follow-up without the start of treatment and 3 after treatment. Amongst the neoadjuvant therapy group, 22 were subjected to exploration and 17 not explored due to various reasons. Thus, of a total 60 (38 + 22) explorations, 50 were resected and 10 were inoperable. R0 resection was achieved in 44/84 (52.4%). The median o
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
Available AR16913

Objectives: Borderline Resectable Pancreatic Tumors
pose a management challenge. We aimed to assess the
impact of multimodality approach on outcomes of borderline
resectable (BR) pancreatic tumors.
Methods: Prospective database (January 2007July
2014) was analyzed retrospectively. Pancreatic tumors
were segregated into BR and locally advanced unresectable
(LA) groups. The decision to operate upfront or
offer neoadjuvant therapy was based on predefined
radiologic criteria and on joint clinic decisions.
Results: There were 104 pancreatic tumors. 84 were
BR and 20 LA. In the BR group, 39 were treated with
neoadjuvant therapy and 38 underwent upfront resection.
7 were lost to follow-up without the start of treatment
and 3 after treatment. Amongst the neoadjuvant
therapy group, 22 were subjected to exploration and 17
not explored due to various reasons. Thus, of a total
60 (38 + 22) explorations, 50 were resected and 10 were
inoperable. R0 resection was achieved in 44/84
(52.4%). The median o

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha